Sentences with phrase «targets as biomarkers»

Not exact matches

Peripheral inflammatory responses may, then, serve as biomarkers and thus serve as targets of immune - based therapies for depression.

«Targeting multiple biomarkers could potentially allow us to identify prostate cancer at its early stages as well as after metastasis in one scan.»

About 15 to 20 % of breast cancers are classified as «triple negative,» so called because these tumors do not express three key proteins that are biomarkers and / or drug targets for breast cancer: the estrogen receptor, the progesterone receptor, and HER2 (a member of the epidermal growth factor receptor family).

As promising new therapies such as those directly targeting survivor motor neuron (SMN) are entering clinical trials for infants, children, and adults with SMA, researchers are searching for biomarkers in blood that can monitor their effectivenesAs promising new therapies such as those directly targeting survivor motor neuron (SMN) are entering clinical trials for infants, children, and adults with SMA, researchers are searching for biomarkers in blood that can monitor their effectivenesas those directly targeting survivor motor neuron (SMN) are entering clinical trials for infants, children, and adults with SMA, researchers are searching for biomarkers in blood that can monitor their effectiveness.

In the end, the identification of microbial species or metabolites that are altered in Parkinson's disease may serve as disease biomarkers or even drug targets, and interventions that correct microbial imbalances may provide safe and effective treatments to slow or halt the progression of often debilitating motor symptoms.

The larger scale Cancer Genome Atlas study provided the information needed to alter proteins or RNA sequences that may act as «drivers» for prognostic biomarkers or therapeutic targets.

«This may serve as a clinically useful biomarker to identify a subset of difficult - to - treat asthmatic children, and targeting the VNN - 1 pathway may be useful as a therapeutic strategy.»

The depth and breadth of information obtained is promoting biomarker discovery, especially potential targets for drug therapies, as well as possibly enabling improved patient stratification for clinical trials and treatment protocols.

Co-researcher Dr Susan Francis, School of Physics, SPMIC added: «The team has a special interest in new types of functional MRI using novel targets like sodium as quantitative biomarkers of disease in the body, in particular in the kidney.

As different cancers express different biomarkers, it might be possible to modify the molecular structure of the ruthenium molecule to target different types of cancer cell.»

«A retrospective analysis of the CHD1 gene in these samples may reveal the potential utility of CHD1 as a biomarker for improved prostate cancer patient stratification and targeted therapy with PARP inhibitors,» notes Johnsen.

This microRNA — miR -124-3p — is thus a potential therapeutic target for novel drug development, and it can serve as a putative biomarker for MDD pathogenesis.

The researchers also are seeking other potential drug targets in the 50 percent of patients who don't have high levels of the anti-death protein, as well as biomarkers in addition to CA125 that could be used to screen for ovarian cancer.

Professor Moffatt said: «The genes we identified represent new potential drug targets for allergic diseases as well as biomarkers that may predict which patients will respond to existing expensive therapies.»

«This research could help us find biomarkers for early detection, as well as provide information for developing targeted therapies for this devastating disease.»

These results not only suggest early mitochondrial biogenesis deficits as a pathogenic mechanism, but also as a potential biomarker and therapeutic target in individuals with Friedreich's ataxia.

Because IBD is a clinically heterogeneous disease with complex mechanisms, a combination of drugs targeting distinct biomarkers might be considered as a potential approach.

«Triple - negative breast cancer continues to be a severe health problem, demanding the consideration of emerging long non-coding RNAs as biomarkers and therapeutic targets in combatting this disease,» said Liquing Yang, Ph.D., assistant professor in the Department of Molecular & Cellular Oncology.

The Identification of ICAM - 1 as a TNBC target and biomarker may lead to the development of a new strategy and platform for addressing a critical gap in TNBC patient care, she added.

«This is, however, an important pre-requisite in order to detect proteins as biomarkers, i.e. as indicators of certain diseases, or new drug targets.»

They immunized them with the antigen α - fetoprotein, which is found in 70 - 80 percent of human liver cancers, and serves as both a biomarker for diagnosing and a target for treating the sixth most common cancer worldwide, He says.

UNC Lineberger researchers reported at the San Antonio Breast Cancer Symposium they have identified biomarkers they believe can be used as part of a larger model to predict how patients with HER2 - positive operative breast cancer will respond to the targeted treatment trastuzumab, commercially known as Herceptin, and chemotherapy.

By developing blood biomarkers and «immunologic signatures» related to antigen - specific T - cell responses, the researchers hope to identify individuals with latent TB infection who are at greatest risk for progression to active disease, allowing development of prevention strategies to target those at highest risk in areas with high rates of infection (usually low - and middle - income countries), as well as high income countries such as the U.S., where factors such as recent infection and HIV co-infection are associated with an increased risk of progression to active TB.

These results suggest that miR - 7 and KLF4 may serve as biomarkers or therapeutic targets for brain metastasis of breast cancer.

Both systems can simultaneously detect many targets such as cytokines, chemokines and inflammatory biomarkers in a single sample that can be serum, plasma and tissue culture supernatants.

This study is good example of a precision medicine themed approach to showing how a mechanistic understanding of the differential gene expression can yield biomarkers that can be used for early detection of disease, as well as potential therapeutic targets.

Our findings show how the tumor microenvironment drives the acquisition of CD39 as an immune regulatory molecule on CD8 + T cells, with implications for defining a biomarker of T cell dysfunction and a target for immunotherapeutic intervention.

This plethora of data can be used to evaluate NUDIX family members as biomarkers or future drug targets.

As MD Anderson moves toward molecular characterization of the cancers of all our patients, allowing their optimal assignments to promising new targeted therapies and potential identification of biomarkers of response and resistance, the department's mission includes thematic translational research and preclinical molecular pathology research.

A new study exploring the NUDIX hydrolases in human cells provides attractive opportunities for expanding the use of this enzyme family as biomarkers and potential novel drug targets.

«We began to mine the data to look for metabolites that might serve as biomarkers or as therapeutic targets,» Chinnaiyan explained.

Their work encompasses several strategies, including: developing FL - HCC animal models to characterize tumor - immune interactions, exploring if a mutated protein associated with FL - HCC could be targeted by immunotherapy, identifying immune checkpoints that could potentially serve as targets for immunotherapy as well as biomarkers for analyzing patients, and evaluating the effectiveness of immunotherapy strategies against FL - HCC patient samples in the lab.

Approximately 50 % of PTCL are unclassifiable and categorized as PTCL, not otherwise specified (PTCL - NOS).1 Using gene expression profiling, PTCL - NOS lymphocytes can be distinguished from normal T lymphocytes, with deregulation of genes involved in apoptosis, proliferation, cell adhesion, and transcription regulation.2 Two subgroups of PTCL - NOS have been identified, which are characterized by high expression of either GATA3 or TBX21 / T - bet transcription factors and downstream target genes.3 However, actionable biomarkers closely related to the pathogenic mechanism need to be further investigated and may become potential therapeutic targets of PTCL - NOS. 4, 5

Susan Amara, USA - «Regulation of transporter function and trafficking by amphetamines, Structure - function relationships in excitatory amino acid transporters (EAATs), Modulation of dopamine transporters (DAT) by GPCRs, Genetics and functional analyses of human trace amine receptors» Tom I. Bonner, USA (Past Core Member)- Genomics, G protein coupled receptors Michel Bouvier, Canada - Molecular Pharmacology of G protein - Coupled Receptors; Molecular mechanisms controlling the selectivity and efficacy of GPCR signalling Thomas Burris, USA - Nuclear Receptor Pharmacology and Drug Discovery William A. Catterall, USA (Past Core Member)- The Molecular Basis of Electrical Excitability Steven Charlton, UK - Molecular Pharmacology and Drug Discovery Moses Chao, USA - Mechanisms of Neurotophin Receptor Signaling Mark Coles, UK - Cellular differentiation, human embryonic stem cells, stromal cells, haematopoietic stem cells, organogenesis, lymphoid microenvironments, develomental immunology Steven L. Colletti, USA Graham L Collingridge, UK Philippe Delerive, France - Metabolic Research (diabetes, obesity, non-alcoholic fatty liver, cardio - vascular diseases, nuclear hormone receptor, GPCRs, kinases) Sir Colin T. Dollery, UK (Founder and Past Core Member) Richard M. Eglen, UK Stephen M. Foord, UK David Gloriam, Denmark - GPCRs, databases, computational drug design, orphan recetpors Gillian Gray, UK Debbie Hay, New Zealand - G protein - coupled receptors, peptide receptors, CGRP, Amylin, Adrenomedullin, Migraine, Diabetes / obesity Allyn C. Howlett, USA Franz Hofmann, Germany - Voltage dependent calcium channels and the positive inotropic effect of beta adrenergic stimulation; cardiovascular function of cGMP protein kinase Yu Huang, Hong Kong - Endothelial and Metabolic Dysfunction, and Novel Biomarkers in Diabetes, Hypertension, Dyslipidemia and Estrogen Deficiency, Endothelium - derived Contracting Factors in the Regulation of Vascular Tone, Adipose Tissue Regulation of Vascular Function in Obesity, Diabetes and Hypertension, Pharmacological Characterization of New Anti-diabetic and Anti-hypertensive Drugs, Hypotensive and antioxidant Actions of Biologically Active Components of Traditional Chinese Herbs and Natural Plants including Polypehnols and Ginsenosides Adriaan P. IJzerman, The Netherlands - G protein - coupled receptors; allosteric modulation; binding kinetics Michael F Jarvis, USA - Purines and Purinergic Receptors and Voltage-gated ion channel (sodium and calcium) pharmacology Pain mechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology of G protein - coupled receptors, in particular opioid receptors, regulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) transporters

Understanding the role of glial cells in glaucoma as well as what happens to the optic nerve where the retinal nerve axons leave the eye may present new therapeutic targets and even potential biomarkers of glaucoma.

Additional goals of the platform include determining biologically relevant doses, identifying biomarkers of sensitivity and resistance, and characterizing adaptive responses as we pursue the potential of combining drug targets.

If these results are confirmed and one or more of these FLT3 - targeted drugs become approved by the FDA, testing for the FLT3 biomarker may eliminate the need for thousands of patients to undergo stem cell transplantation (each allogeneic transplant costs hundreds of thousands of dollars and place recipients at grave risk of infection and other complications such as Graft vs. Host disease).

But the most important implication of our findings would be to use STAT5 as the target for chemoprevention, in which case it would also serve as the optimal biomarker.